Palbocent 125 mg Palbociclib sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. This medicine is manufactured by Beacon.

Palbocent 125 mg Palbociclib-Package Insert

Description

Palbocent 125 mg is an oral medication used to treat specific types of breast cancer in adults. It is prescribed by a doctor based on its proven benefits for the cancer type. Palbociclib is a targeted therapy that blocks the enzymes CDK4 and CDK6, which are crucial for cell division. Blocking these proteins slows down cell division, thereby slowing down cancer growth. It is used in combination with other cancer treatments like aromatase inhibitors or fulvestrants, depending on clinical factors. Palbociclib is a cyclin-dependent kinase (CDK) 4/6 inhibitor that works by blocking the activity of CDK4/6 proteins, which can slow down the growth and spread of cancer cells.

By inhibiting the CDK4/6 proteins, Palbocent 125 mg effectively disrupts the signaling pathway responsible for cell division. This targeted therapy has shown promising results in clinical trials, particularly in the treatment of hormone receptor-positive metastatic breast cancer. Additionally, the use of Palbocent in combination with other cancer treatments has been found to enhance its effectiveness and improve overall patient outcomes. Overall, Palbocent represents a significant advancement in cancer treatment, offering new hope to patients with specific types of cancer.

Indications

Palbocent is a highly effective treatment for adult patients with hormone receptor-positive, HER2-negative, advanced, or metastatic breast cancer.

It is used in combination with aromatase inhibitors (AI) as initial endocrine-based therapy or with Fulvestrant in patients who have disease progression after endocrine therapy. Clinical trials have shown thatPalbocent significantly improves progression-free survival and overall survival in these patients.

Mechanism of Actions

Palbocent is a drug that inhibits the ATP pocket of CDK4 and 6, preventing them from binding to target proteins and preventing the cell cycle from progressing from the G1 to S phases. This leads to cell cycle arrest and apoptosis, which is programmed cell death. Palbocent is particularly effective against cancer cells that rely on CDK4 and 6 for growth and survival, including breast cancer, ovarian, endometrial, and lung cancer.

Clinical trials have shown that Palbocent significantly improves progression-free survival and overall survival in patients with advanced or metastatic breast cancer. It is now a standard of care treatment for this type of breast cancer. Palbocent is a cyclin-dependent kinase 4/6 inhibitor with an IC50 of 9–15 nmol/L, and its inhibition prevents cell cycle progression in cells whose pathway is functioning, including the phosphorylation of retinoblastoma protein and the E2F family of transcription factors.

Dosage & Administration

Palbocent’s recommended dosage is 125 mg taken orally once daily for 21 days in a row, followed by a 7-day break from treatment to make up a full 28-day cycle. You can take Palbocent with or without food.

Palbocent is frequently administered along with a fulvestrant or an aromatase inhibitor (AI). When combined with Palbocent, the recommended dose of AI or fulvestrant is the same as the dose recommended for these medications when taken on their own.

Patients who experience specific side effects, such as neutropenia (low white blood cell count) or liver issues, may need to adjust their dosage.

Here are some additional dosage and administration instructions for Palbocent:

Palbocent tablets should be swallowed whole (do not chew, crush, or split them prior to swallowing).
Patients should be encouraged to take their dose at approximately the same time each day.
If the patient vomits or misses a dose, an additional dose should not be taken that day. The next prescribed dose should be taken at the usual time.
Palbociclib is a CYP3A4 substrate, so it should be used with caution in patients who are taking strong CYP3A4 inhibitors. If a strong CYP3A4 inhibitor cannot be avoided, the dose of palbociclib should be reduced to 75 mg once daily.
Patients should avoid grapefruit or grapefruit juice during IBRANCE treatment.

Storage: Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.

Side Effects of Palbocent 125 mg Palbociclib

The most common side effects of palbociclib include:

Neutropenia (low white blood cell count)
Fatigue
Decreased appetite
Hair loss
Nausea
Mouth sores
Diarrhea
Anemia (low red blood cell count)
Thrombocytopenia (low platelet count)
Liver problems
Kidney problems

Palbociclib can also cause more serious side effects, such as:

Heart problems, such as QT prolongation (a condition that can cause abnormal heart rhythms) and cardiomyopathy (weakening of the heart muscle)
Pneumonitis (inflammation of the lungs)
Hepatotoxicity (liver damage)
Severe infections
Bone marrow suppression
Secondary malignancies (new cancers that develop as a result of cancer treatment)

It is important to talk to your doctor about the risks and benefits of palbociclib before starting treatment. Your doctor will monitor you closely for side effects during treatment and will adjust your dose as needed.

Riboiciclib vs Palbociclib

Ribociclib and palbociclib are both cyclin-dependent kinase (CDK) 4/6 inhibitors that are used to treat hormone receptor (HR)-positive and HER-2-negative advanced or metastatic breast cancer. They are both highly effective drugs, but there are some key differences between the two.

Efficacy

In clinical trials, both ribociclib and palbociclib were shown to significantly improve progression-free survival (PFS) and overall survival (OS) in patients with HR-positive, HER-2-negative advanced or metastatic breast cancer. However, ribociclib has shown a slight advantage over palbociclib in terms of OS. In a meta-analysis of clinical trial data, ribociclib was associated with a longer OS than palbociclib (median OS of 63.8 months vs. 57.2 months).

Safety

Both ribociclib and palbociclib are generally well-tolerated drugs, but they can cause some common side effects, such as neutropenia (low white blood cell count), fatigue, and decreased appetite. Palbociclib is associated with a higher risk of neutropenia than ribociclib, but ribociclib is associated with a higher risk of diarrhea.

Both drugs can also cause more serious side effects, such as heart problems and pneumonitis (inflammation of the lungs). However, these side effects are relatively rare.

Cost

Ribociclib is typically more expensive than palbociclib. However, the cost of both drugs can vary depending on insurance coverage and other factors.

Overall

Both ribociclib and palbociclib are highly effective and well-tolerated drugs for the treatment of HR-positive and HER-2-negative advanced or metastatic breast cancer. Ribociclib has shown a slight advantage over palbociclib in terms of OS, but palbociclib is less expensive. The best choice of drug for a particular patient will depend on individual factors, such as the patient’s overall health, insurance coverage, and personal preferences.

Palbocent 125 mg Palbociclib Cost

The cash price for Ibrance (palbociclib) is around $13,000 to $13,500 for a supply of 21 capsules, using an online coupon. However, most people do not pay this price. This price is for customers paying cash only, with a discount coupon, and is not valid with insurance plans.
If you have commercial insurance, check with Pfizer, the manufacturer of Ibrance, to determine if you may be eligible for the $0 copay card. Savings may be available for other types of insurance or if you have no insurance. Call 1-844-9-IBRANCE (Monday–Friday 8 AM–8 PM ET).
Ibrance (palbociclib) is used as part of a treatment regimen in men and women to treat HR-positive, HER2-negative breast cancer that has spread to other parts of the body.

See other brand medicine with the same generic name Palbonix-125mg, Palboxen-125mg

Read to know more about breast cancer : Breast Cancer Awareness

Frequently Asked Questions About Palbocent 125 mg Palbociclib

Q: What is Palbocent 125 mg Palbociclib?

Palbocent (Palbociclib) is a targeted or biological therapy drug. Palbocent is used alongside hormone (endocrine) therapy to treat breast cancer. Palbociclib is the drug’s non-branded name. Its brand name is Ibrance. It belongs to a group of drugs called CDK (cyclin-dependent kinase) inhibitors. for more information visit

Q: How does Palbocent 125 mg Work?

Palbocent 125 mg works by blocking these proteins, helping to stop the cancer cells from growing and dividing. When combined with hormone therapies that block the effects of estrogen on cancer cells, palbociclib helps to delay the growth of ER+, HER2-negative breast cancer. for more information visit

Q: What happens if I miss a dose of Palbocent?

If you miss a palbociclib dose or are sick (vomit) soon after taking it, do not take an extra dose to make up for the one you missed. Keep to your usual amount and speak to someone in your treatment team.

Storage: Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.